投资机构Jonestrading近日宣布，对Neuroone Medical Technologies Corp（股票代码：NMTC）的目标股价进行重大调整。该机构将目标价从原先的1.5美元大幅上调至8美元，这一调整主要是为了反映该公司近期实施的1比6反向股票分割。
反向股票分割是指将多股合并为一股的资本重组操作。Neuroone Medical Technologies此次实施的1比6并股方案，意味着每6股现有普通股将合并为1股新股。这种操作通常会导致每股价格同比上涨，而公司总市值保持不变。
Jonestrading此次调整目标价的行为，体现了专业机构对上市公司资本结构变化的及时反应。通过将目标价从1.5美元调整为8美元，该机构确保了投资建议与公司新的股本结构保持一致，为投资者提供了更准确的价值参考。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.